Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: In vitro effect of extra drug-free GlyPheLeuGly sequences

Journal of Controlled Release

Volumn 127, Issue 2, 2008, Pages 110-120

  Rihova B ^a   Strohalm, J ^b   Hovorka, O ^a   Subr V ^b   Etrych, T ^b   Chytil, P ^b   Pola, R ^b   Plocova D ^b   Boucek J ^a,c   Ulbrich, K ^b  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^b INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Apoptosis; Cancer cell line; Extra side chain; GlyGly; GlyPheLeuGly; HPMA; Necrosis

Indexed keywords

CANCER CELL LINE; DOXORUBICIN RELEASE; EXTRA SIDE CHAINS; NECROSIS;

BIOACTIVITY; CARBOXYLATION; CELL DEATH; COPOLYMERS; CYTOTOXICITY; POLYMERIZATION;

DRUG PRODUCTS;

AMINO ACID DERIVATIVE; DOXORUBICIN; GLYCYLGLYCINE; GLYCYLPHENYLALANYLLEUCYLGLYCINE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; OLIGOPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG MECHANISM; DRUG RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; NECROSIS; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; RAJI CELL; SPLEEN CELL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DOXORUBICIN; HUMANS; METHACRYLATES; MICE; MICE, INBRED BALB C; NECROSIS; OLIGOPEPTIDES; POLYMETHACRYLIC ACIDS; SPLEEN;

EID: 41449110512     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.01.003     Document Type: Article

References (32)

1. Říhová B., and Kopeček J. Biological properties of targetable poly[N-(2-hydroxypropyl)methacrylamide]-antibody conjugates. J. Control. Release 2 (1985) 289-310
2. Duncan R., Cable H.C., Lloyd J.B., Rejmanová P., and Kopeček J. Polymers containing enzymatically degradable bonds. 7. Design of oligopeptide side chains in poly [N-(2-hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes. Makromol. Chem. 184 (1984) 1997-2008
3. J. Kopeček, P. Rejmanová, J. Strohalm, K. Ulbrich, B. Říhová, V. Chytrý, J.B. Lloyd, R. Duncan, Synthetic polymeric drugs (1991), U.S.Patent 5,037,883.
4. Etrych T., Jelínková M., Říhová B., and Ulbrich K. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties. J. Control. Release 73 (2001) 89-102
5. Mrkvan T., Šírová M., Etrych T., Chytil P., Strohalm J., Plocová D., Ulbrich K., and Říhová B. Chemotherapy based on HPMA copolymer conjugates with pH-controlled release of doxorubicin triggers anti-tumor immunity. J. Control.Release 110 (2005) 119-129
6. Duncan R., Kopeček J., and Lloyd J.B. Development of N-(2-hydroxypropyl)methacrylamide copolymers as carriers of therapeutic agents. In: Chiellini E., and Giusti P. (Eds). Polymers in Medicine, Biomedical and Pharmacological Applications (1983), Plenum Press, New York 97-113
7. Kopeček J., Rejmanová P., and Chytrý V. Polymers containing enzymatically degradable bonds. I. Chymotrypsin catalyzed hydrolysis of p-nitroanilides of phenylalanine and tyrosine attached to side-chains of copolymers of N-(2-hydroxypropyl)methacrylamide. Makromol. Chem. 182 (1981) 799-809
8. Duncan R., Cable H.C., Lloyd J.B., Rejmanová P., and Kopeček J. Degradation of side-chains of N-(2-hydroxypropyl)methacrylamide copolymers by lysosomal thiol-proteinases. Biosci. Rep. 2 (1982) 1041-1046
9. Duncan R., Rejmanová P., Kopeček J., and Lloyd J.B. Pinocytic uptake and intracellular degradation of N-(2-hydroxypropyl)methacrylamide copolymers. A potential drug delivery system. Biochim. Biophys. Acta 678 (1981) 143-150
10. Duncan R. N-(2-hydroxypropyl)methacrylamide copolymer conjugates. In: Kwon G.S. (Ed). Polymeric Drug Delivery Systems (Drugs and the Pharmaceutical Sciences) 148 (2007) 1-92
11. a: degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacryamide copolymers by bovine spleen cathepsin B. Makromol. Chem. 184 (1983) 2009-2020
12. Duncan R., Kopečková-Rejmanová P., Strohalm J., Hume I.C., Cable H.C., Pohl J., Lloyd J.B., and Kopeček J. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro. Br. J. Cancer 55 (1987) 165-174
13. O'Hare K.B., Duncan R., Strohalm J., Ulbrich K., and Kopečková P. Polymeric drug-carriers containing doxorubicin and melanocyte stimulating hormone. In vitro and in vivo Evaluation Against Murine Melanoma. J. Drug Target 1 (1993) 217-229
14. 2 mice. Br. J. Cancer 63 (1991) 859-866
15. Říhová B., Kopečková P., Strohalm J., Rossmann P., Větvička V., and Kopeček J. Antibody-directed affinity therapy applied to the immune system: in vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody. Clin. Immunol. Immunopathol. 6 (1988) 100-114
16. Vasey P.A., Kaye S.B., Morrison R., Twelves Ch., Wilson P., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T., Burtles S., Fraier D., Frigerio E., and Cassidy J. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents - drug-polymer conjugates. Clin. Cancer Res. 5 (1999) 83-94
17. Julyan P.J., Seymour L.W., Ferry D.R., Daryani S., Boivin Ch.M., Doran J., David M., Anderson D., Christodoulou Ch., Young A.M., Hesselwood S., and Kerr D.J. Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. J. Control. Release 57 (1999) 281-290
18. Jelínková M., Strohalm J., Plocová D., Šubr V., Šťastný M., Ulbrich K., and Říhová B. Targeting of human and mouse T-lymphocytes by monoclonal antibody-HPMA copolymer-doxorubicin conjugates directed against different T-cell surface antigens. J. Control. Release 52 (1998) 253-270
19. Hovorka O., Šťastný M., Etrych T., Šubr V., Strohalm J., Ulbrich K., and Říhová B. Differences in the intracellular fate of free and polymer-bound doxorubicin. J. Control. Release 80 (2002) 101-117
20. N. Mongelli, E. Pesenti, A. Suarato, G. Biasoli, Polymer-bound paclitaxel derivatives. US Patent 1994: 5,362,831.
21. Kopeček J. Biodegradation of polymers for biomedical use. In: Benoit H., and Rempp P. (Eds). IUPAC Macromolecules (1982), Pergamon Press, Oxford 305-320
22. Říhová B., Šubr V., Etrych T., Chytil P., Hovorka O., and Ulbrich K. Mistake lasting twenty years?. To be in vitro effective doxorubicin does not have to be released from its polymeric HPMA-based carrier. Twelfth International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City (February 21-24 2005) 190 Abstracts
23. Fiallo M., Laigle A., Borrel M.N., and Garnier-Suillerot A. Accumulation of degradation products of doxorubicin and pirarubicin formed in cell culture medium within sensitive and resistant cells. Biochem. Pharmacol. 45 (1993) 659-665
24. Loadman P.M., Bibby M.C., Double J.A., Al-Shakhaa W.M., and Duncan R. Pharmacokinetics of PK1 and doxorubicin in experimental colon tumour models with differing responses to PK1. Clin. Cancer Res 5 (1999) 3682-3688
25. Říhová B., Strohalm J., Prausová J., Kubáčková K., Jelínková M., Rozprimová L., Šírová M., Plocová D., Etrych T., Šubr V., Mrkvan T., Kovář M., and Ulbrich K. Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data. J. Control. Release 91 (2003) 1-16
26. Caiolfa V.R., Zamai M., Fiorino A., Frigerio E., Pellizzoni C., d'Argy R., Ghiglieri A., Castelli M.G., Farao M., Pesenti E., Gigli M., Angelucci F., and Suarato A. Polymer-bound campthotecin: initial biodistribution and antitumour activity studies. J. Control. Release 65 (2000) 105-119
27. Fraier D., Frigerio E., Brianceschi G., Casati M., Benecchi A., and James C. Determination of MAG-campthotecin, a new polymer-bound campthotecin derivative, and free campthotecin in dog plasma by HPLC with fluorimetric detection. J. Pharm. Biomed. Anal. 22 (2000) 505-514
28. Sarapa N., Britto M.R., Speed W., Jannuzzo M., Breda M., James C.A., Porro M., Rocheti M., Wanders A., Mahteme H., and Nygren P. Assessment of normal and tumour tissue uptake of MAG-CPT, a polymer-bound prodrug of campthotecin, in patients undergoing elective surgery for colorectal carcinoma. Cancer Chemother. Pharmacol. 52 (2003) 424-430
29. Wachters F.M., Groen H.J.M., Maring J.G., Gietama J.A., Porro M., Dumez H., de Vries G.E., and van Osterom A.T. A phase I study with MAG-campthotecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours. Br. J. Cancer 90 (2004) 2261-2267
30. Hovorka O., Etrych T., Šubr V., Strohalm J., Ulbrich K., and Říhová B. HPMA based macromolecular therapeutics: internalization, intracellular pathway and cell death depend on the character of covalent bond between the drug and the peptidic spacer and also on spacer composition. J. Drug Target. 14 (2006) 391-403
31. 125I] daunomycin. J. Control. Release 10 (1989) 37-49
32. Duncan R., Kopečková P., Strohalm J., Hume I.C., Lloyd J.B., and Kopeček J. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia. Br. J. Cancer 57 (1988) 147-156